ABSTRACT
How rapid HIV infection progresses to AIDS and to death is affected by different factors. This study explores survival times and associated survival factors from treatment initiation to death or censoring in antiretroviral therapy-experienced HIV-seropositive adults in Malawi from 2004-2015.
A multicentre non-concurrent, retrospective cohort study was undertaken from eight ART Centres where patients’ medical records (PMRs) of HIV-positive adult patients aged 15+ years were reviewed. A life table, the Kaplan-Meier log-rank, and Cox Proportion Hazard regression were used to calculate survival time-to-death and its correlates, respectively. Hazard ratio with 95%CI and p<0.05 were used to declare statistical significance.
Data for (n=9,953) patients were abstracted from PMRs. Patients median age was 40 (IQR: 33-48 years). 60.8% were females, 45.2% were aged 20-39 years, and 78.8% were married. At treatment initiation, 48.1% had advanced HIV disease clinical stage III, 24.5% had WHO stage IV, whereas 27.5% were asymptomatic – of which, 24.9% and 2.6% initiated ART due to low CD4+ count and PMTCT’s Option-B+ eligibility criteria, respectively. Survival function findings revealed that each patient had a single entry into the study. Exit time ranged from 1 to 9,224 days with the mean value of 2,421.9 days, occurring at the rate of 0.00004883 event-failure per-person-day. Time-to-death was observed at the rate of 1.78/100 person-years-at-risk (PYAR). 213 deaths (18.1%) occurred early in year-one post-ART-initiation. Deaths occurred more among persons of 20-39 years (N=470, 39.97%), and of 40-54 years (N=483, 41.07%), and was mostly due to mycobacterial pathogenic conditions (N=106, 37.3%) in particular TB infection (N=103); most of which were PTB cases (N=69, 66.9%). Mortality was high in Southern region (63.1%, N=743) but was least in Northern region (N=313) [p<0.0001]. In a multivariate Cox regression predictive model, males gender (aHR=1.42), patients age-groups of 20-39 years (aHR=1.63), 40-54 years (aHR=1.71), and 55+ years (aHR=2.66), Mzuzu Central hospital ART centre (aHR=2.66), Thyolo District hospital ART centre (aHR=3.02), semi-rural areas (aHR=1.30), urban areas (aHR=0.80), being single (aHR=0.86), chronic cough and/or breathlessness (aHR=1.19), chronic diarrhoea or weight loss (aHR=1.43), chronic fever and/or severe headache (aHR=1.30), skin or oral lesion (aHR=1.33), WHO clinical stage III (aHR=17.90), WHO clinical stage IV (aHR=20.09), low baseline CD4 count <250 cells/µL, (aHR=1.17), high baseline VL>1,000 copies/mL (aHR=2.46), Nevirapine-based therapies (aHR=1.14), and HIV duration of 3-5 years (aHR=1.17), 6-10 years (aHR=1.19) and >10 years (aHR=1.16) were all statistically significantly associated with time-to-death.
This study has demonstrated survival factors associated with time-to-death among HIV-positive adults in Malawi. In order to effectively reduce AIDS mortality and win the war against AIDS-related death, the need to critically address and carefully prioritise the identified factors in HIV/AIDS management is great and cannot be overemphasised.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The University of Warwick Research Ethics Committee (the Biomedical and Scientific Research Ethics Committee) and the Malawi Research Ethics Committee (the National Health Sciences Research Committee) in the Ministry of Health granted the ethics approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the corresponding author.
